{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:09:08Z","timestamp":1787792948690,"version":"build-2784847793"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplantation Direct"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The goal of treating chronic hepatitis C virus (HCV) infection is sustained virologic response (SVR). There is concern that despite achieving SVR, replication-competent HCV may be sequestered at low levels within the liver and could theoretically reactivate with immunosuppression. We report transplantation of a HCV-seropositive liver donor, who achieved SVR, into a seronegative patient without HCV reactivation despite profound immunosuppression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>Retrospective chart review.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We present a 21-year-old male who was HCV seronegative and received a liver transplant from a donor who had been treated for HCV and achieved SVR. The liver recipient, despite developing severe acute graft rejection and undergoing intense immunosuppression with T cell\u2013depleting antibodies, did not become HCV RNA-positive with a follow up period of 8 months. The recipient was HCV seronegative before transplant, but became HCV seropositive immediately posttransplant. The antibodies were undetectable after 97 days, in keeping with a passive antibody transmission or B lymphocyte transmission with the graft.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>To the best of our knowledge, this is the first reported case of an HCV seropositive liver allograft transplanted into an HCV-negative recipient who subsequently received intense immunosuppression. This case, therefore, is an encouraging and novel step in liver transplantation, and demonstrates that SVR may be closer to a true \u201ccure\u201d of HCV in the donor population and that, even in circumstances of very potent immunosuppression in the recipient, this SVR is sustained.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000000763","type":"journal-article","created":{"date-parts":[[2018,2,4]],"date-time":"2018-02-04T23:26:53Z","timestamp":1517786813000},"page":"e347","source":"Crossref","is-referenced-by-count":4,"title":["Transplantation of a Liver Allograft From a Hepatitis C Virus Seropositive Donor With Previous Sustained Virologic Response to an Uninfected Recipient Suffering Steroid Refractory Acute Graft Rejection With No Evidence of HCV Transmission"],"prefix":"10.1097","volume":"4","author":[{"given":"Robert A.","family":"Mitchell","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trana","family":"Hussaini","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan H.","family":"Yau","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mel","family":"Krajden","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa J.","family":"Wright","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles H.","family":"Scudamore","sequence":"additional","affiliation":[{"name":"Division of General Surgery, University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Marquez Azalgara","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried R.","family":"Erb","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,3]]},"reference":[{"key":"bib1-20231002","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"bib2-20231002","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2010.07.009","article-title":"A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin","volume":"139","year":"2010","journal-title":"Gastroenterology"},{"key":"bib3-20231002","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/jmv.21257","article-title":"Immune suppression leading to hepatitis C virus re-emergence after sustained virological response","volume":"80","year":"2008","journal-title":"J Med Virol"},{"key":"bib4-20231002","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1086\/508198","article-title":"Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment","volume":"43","year":"2006","journal-title":"Clin Infect Dis"},{"key":"bib5-20231002","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/hep.25964","article-title":"Sustained virologic response: is this equivalent to cure of chronic hepatitis C?","volume":"57","year":"2013","journal-title":"Hepatology"},{"key":"bib6-20231002","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/10428190500062932","article-title":"Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations","volume":"46","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"bib7-20231002","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1046\/j.1537-2995.1991.31191096190.x","article-title":"Red cell antibodies arising from solid organ transplants","volume":"31","year":"1991","journal-title":"Transfusion"},{"key":"bib8-20231002","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1086\/432917","article-title":"Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: evidence for an occult viral reservoir","volume":"192","year":"2005","journal-title":"J Infect Dis"},{"key":"bib9-20231002","first-page":"100","article-title":"Utilization of organs from donors according to hepatitis c antibody and nucleic acid testing status: time for change","volume":"148","year":"2017","journal-title":"Am J Transplant"},{"key":"bib10-20231002","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMc1705221","article-title":"Trial of transplantation of HCV-infected kidneys into uninfected recipients","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"key":"bib12-20231002","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1111\/ajt.14381","article-title":"The American Society of Transplantation Consensus Conference on the use of hepatitis C viremic donors in solid organ transplantation","volume":"17","year":"2017","journal-title":"Am J Transplant"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01845228-201803000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T07:03:25Z","timestamp":1696230205000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01845228-201803000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":11,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000000763","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}